<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37563264</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4766</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature reviews. Neurology</Title><ISOAbbreviation>Nat Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases.</ArticleTitle><Pagination><StartPage>525</StartPage><EndPage>541</EndPage><MedlinePgn>525-541</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41582-023-00846-7</ELocationID><Abstract><AbstractText>TAR DNA-binding protein 43 (TDP43) is a focus of research in late-onset dementias. TDP43 pathology in the brain was initially identified in amyotrophic lateral sclerosis and frontotemporal lobar degeneration, and later in Alzheimer disease (AD), other neurodegenerative diseases and ageing. Limbic-predominant age-related TDP43 encephalopathy (LATE), recognized as a clinical entity in 2019, is characterized by amnestic dementia resembling AD dementia and occurring most commonly in adults over 80 years of age. Neuropathological findings in LATE, referred to as LATE neuropathological change (LATE-NC), consist of neuronal and glial cytoplasmic TDP43 localized predominantly in limbic areas with or without coexisting hippocampal sclerosis and/or AD neuropathological change and without frontotemporal lobar degeneration or amyotrophic lateral sclerosis pathology. LATE-NC is frequently associated with one or more coexisting pathologies, mainly AD neuropathological change. The focus of this Review is the pathology, genetic risk factors and nature of the cognitive impairments and dementia in pure LATE-NC and in LATE-NC associated with coexisting pathologies. As the clinical and cognitive profile of LATE is currently not easily distinguishable from AD dementia, it is important to develop biomarkers to aid in the diagnosis of this condition in the clinic. The pathogenesis of LATE-NC should be a focus of future research to form the basis for the development of preventive and therapeutic strategies.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nag</LastName><ForeName>Sukriti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Department of Pathology (Neuropathology), Rush University Medical Center, Chicago, IL, USA. Sukriti_Nag@Rush.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-9482-1752</Identifier><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Department of Pathology (Neuropathology), Rush University Medical Center, Chicago, IL, USA. Julie_A_Schneider@Rush.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG042210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG067482</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG022018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurol</MedlineTA><NlmUniqueID>101500072</NlmUniqueID><ISSNLinking>1759-4758</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000723354">limbic-predominant age-related TDP-43 encephalopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>10</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37563264</ArticleId><ArticleId IdType="doi">10.1038/s41582-023-00846-7</ArticleId><ArticleId IdType="pii">10.1038/s41582-023-00846-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ou, S. H., Wu, F., Harrich, D., Garcia-Martinez, L. F. &amp; Gaynor, R. B. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol. 69, 3584&#x2013;3596 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7745706</ArticleId><ArticleId IdType="pmc">189073</ArticleId><ArticleId IdType="doi">10.1128/jvi.69.6.3584-3596.1995</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602&#x2013;611 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId><ArticleId IdType="doi">10.1126/science.1134108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota, O. et al. Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol. 120, 55&#x2013;66 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20512649</ArticleId><ArticleId IdType="pmc">2901929</ArticleId><ArticleId IdType="doi">10.1007/s00401-010-0702-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz, W. D., Monsell, S. E., Schmitt, F. A., Kukull, W. A. &amp; Nelson, P. T. Hippocampal sclerosis of aging is a key Alzheimer&#x2019;s disease mimic: clinical-pathologic correlations and comparisons with both Alzheimer&#x2019;s disease and non-tauopathic frontotemporal lobar degeneration. J. Alzheimers Dis. 39, 691&#x2013;702 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24270205</ArticleId><ArticleId IdType="pmc">3946156</ArticleId><ArticleId IdType="doi">10.3233/JAD-131880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142, 1503&#x2013;1527 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31039256</ArticleId><ArticleId IdType="pmc">6536849</ArticleId><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. et al. LATE to the PART-y. Brain 142, e47 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31359030</ArticleId><ArticleId IdType="pmc">6736234</ArticleId><ArticleId IdType="doi">10.1093/brain/awz224</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi, J. Debate sparks over LATE, a recently recognized dementia. J. Am. Med. Assoc. 322, 914&#x2013;916 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.12232</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. Reply: LATE to the PART-y. Brain 142, e48 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31359039</ArticleId><ArticleId IdType="pmc">6931389</ArticleId><ArticleId IdType="doi">10.1093/brain/awz226</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine, T. J. et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 123, 1&#x2013;11 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22101365</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee, A. C. et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J. Neuropathol. Exp. Neurol. 69, 918&#x2013;929 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20720505</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e3181ee7d85</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab, C., Arai, T., Hasegawa, M., Yu, S. &amp; McGeer, P. L. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J. Neuropathol. Exp. Neurol. 67, 1159&#x2013;1165 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19018245</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e31818e8951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton, C. F. et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J. Biol. Chem. 285, 6826&#x2013;6834 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20040602</ArticleId><ArticleId IdType="doi">10.1074/jbc.M109.061846</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti, E. &amp; Baralle, F. E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem. 276, 36337&#x2013;36343 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId><ArticleId IdType="doi">10.1074/jbc.M104236200</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. R., King, O. D., Shorter, J. &amp; Gitler, A. D. Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 201, 361&#x2013;372 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23629963</ArticleId><ArticleId IdType="pmc">3639398</ArticleId><ArticleId IdType="doi">10.1083/jcb.201302044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompean, M. et al. The TDP-43 N-terminal domain structure at high resolution. FEBS J. 283, 1242&#x2013;1260 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26756435</ArticleId><ArticleId IdType="doi">10.1111/febs.13651</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison, A. F. &amp; Shorter, J. RNA-binding proteins with prion-like domains in health and disease. Biochem. J. 474, 1417&#x2013;1438 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28389532</ArticleId><ArticleId IdType="doi">10.1042/BCJ20160499</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer, E. M. J. et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry 92, 86&#x2013;95 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33177049</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, L. &amp; Shorter, J. Biology and pathobiology of TDP-43 and emergent therapeutic strategies. Cold Spring Harb. Perspect. Med. 7, a024554 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27920024</ArticleId><ArticleId IdType="pmc">5580514</ArticleId><ArticleId IdType="doi">10.1101/cshperspect.a024554</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, J., Wang, L., Huntley, M. L., Perry, G. &amp; Wang, X. Pathomechanisms of TDP-43 in neurodegeneration. J. Neurochem. https://doi.org/10.1111/jnc.14327 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14327</ArticleId><ArticleId IdType="pubmed">29524228</ArticleId><ArticleId IdType="pmc">6110993</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A. &amp; Patel, B. K. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 12, 25 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30837838</ArticleId><ArticleId IdType="pmc">6382748</ArticleId><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalmansingh, A. S., Urekar, C. J. &amp; Reddi, P. P. TDP-43 is a transcriptional repressor: the testis-specific mouse acrv1 gene is a TDP-43 target in vivo. J. Biol. Chem. 286, 10970&#x2013;10982 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21252238</ArticleId><ArticleId IdType="pmc">3064152</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.166587</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum, B. D., Chitta, R. K., High, A. A. &amp; Taylor, J. P. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J. Proteome Res. 9, 1104&#x2013;1120 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20020773</ArticleId><ArticleId IdType="pmc">2897173</ArticleId><ArticleId IdType="doi">10.1021/pr901076y</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling, J. P., Pletnikova, O., Troncoso, J. C. &amp; Wong, P. C. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650&#x2013;655 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26250685</ArticleId><ArticleId IdType="pmc">4825810</ArticleId><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling, S. C., Polymenidou, M. &amp; Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416&#x2013;438 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23931993</ArticleId><ArticleId IdType="pmc">4411085</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz, L. et al. ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. J. Neurosci. 34, 4167&#x2013;4174 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24647938</ArticleId><ArticleId IdType="pmc">3960463</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2350-13.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti, E. et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 280, 37572&#x2013;37584 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16157593</ArticleId><ArticleId IdType="doi">10.1074/jbc.M505557200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara, Y. &amp; Mieda-Sato, A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl Acad. Sci. USA 109, 3347&#x2013;3352 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22323604</ArticleId><ArticleId IdType="pmc">3295278</ArticleId><ArticleId IdType="doi">10.1073/pnas.1112427109</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou, M. et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 14, 459&#x2013;468 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21358643</ArticleId><ArticleId IdType="pmc">3094729</ArticleId><ArticleId IdType="doi">10.1038/nn.2779</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey, J. R. et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 14, 452&#x2013;458 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21358640</ArticleId><ArticleId IdType="pmc">3108889</ArticleId><ArticleId IdType="doi">10.1038/nn.2778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala, Y. M. et al. Structural determinants of the cellular localization and shuttling of TDP-43. J. Cell Sci. 121, 3778&#x2013;3785 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId><ArticleId IdType="doi">10.1242/jcs.038950</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid, B. et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc. Natl Acad. Sci. USA 110, 4986&#x2013;4991 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23457265</ArticleId><ArticleId IdType="pmc">3612625</ArticleId><ArticleId IdType="doi">10.1073/pnas.1218311110</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman, M. S., Trojanowski, J. Q. &amp; Lee, V. M. TDP-43: a novel neurodegenerative proteinopathy. Curr. Opin. Neurobiol. 17, 548&#x2013;555 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17936612</ArticleId><ArticleId IdType="pmc">2678676</ArticleId><ArticleId IdType="doi">10.1016/j.conb.2007.08.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag, S. et al. TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 6, 33 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29716643</ArticleId><ArticleId IdType="pmc">5928580</ArticleId><ArticleId IdType="doi">10.1186/s40478-018-0531-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, R. S. et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 70, 1418&#x2013;1424 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24080705</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.3961</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa, M. et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 64, 60&#x2013;70 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18546284</ArticleId><ArticleId IdType="pmc">2674108</ArticleId><ArticleId IdType="doi">10.1002/ana.21425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. J. et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA 106, 7607&#x2013;7612 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19383787</ArticleId><ArticleId IdType="pmc">2671323</ArticleId><ArticleId IdType="doi">10.1073/pnas.0900688106</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 117, 137&#x2013;149 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19125255</ArticleId><ArticleId IdType="pmc">2693625</ArticleId><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz, C. et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann. Neurol. 61, 435&#x2013;445 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17469117</ArticleId><ArticleId IdType="pmc">2677204</ArticleId><ArticleId IdType="doi">10.1002/ana.21154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita, A., Tomimoto, H., Suenaga, T., Akiguchi, I. &amp; Kimura, J. Ubiquitin-related cytoskeletal abnormality in frontotemporal dementia: immunohistochemical and immunoelectron microscope studies. Acta Neuropathol. 94, 67&#x2013;72 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9224532</ArticleId><ArticleId IdType="doi">10.1007/s004010050673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, W. L. &amp; Dickson, D. W. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 116, 205&#x2013;213 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18607609</ArticleId><ArticleId IdType="pmc">2706695</ArticleId><ArticleId IdType="doi">10.1007/s00401-008-0408-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarutani, A. et al. Ultrastructural and biochemical classification of pathogenic tau, &#x3b1;-synuclein and TDP-43. Acta Neuropathol. 143, 613&#x2013;640 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35513543</ArticleId><ArticleId IdType="pmc">9107452</ArticleId><ArticleId IdType="doi">10.1007/s00401-022-02426-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka, T. et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4, 124&#x2013;134 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong, L. K., Uryu, K., Trojanowski, J. Q. &amp; Lee, V. M. TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 16, 41&#x2013;51 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18097159</ArticleId><ArticleId IdType="doi">10.1159/000109758</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, B. S. et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 284, 20329&#x2013;20339 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19465477</ArticleId><ArticleId IdType="pmc">2740458</ArticleId><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni, D. et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 601, 139&#x2013;143 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34880495</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04199-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag, S. et al. TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology 88, 653&#x2013;660 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28087828</ArticleId><ArticleId IdType="pmc">5317379</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003610</ArticleId></ArticleIdList></Reference><Reference><Citation>James, B. D. et al. TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain 139, 2983&#x2013;2993 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27694152</ArticleId><ArticleId IdType="pmc">5091047</ArticleId><ArticleId IdType="doi">10.1093/brain/aww224</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag, S. et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann. Neurol. 77, 942&#x2013;952 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25707479</ArticleId><ArticleId IdType="pmc">4447563</ArticleId><ArticleId IdType="doi">10.1002/ana.24388</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, S. J., Dugger, B. N. &amp; Beach, T. G. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol. 126, 51&#x2013;57 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23604587</ArticleId><ArticleId IdType="pmc">3691299</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1110-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino, A. et al. Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol. Commun. 3, 35 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26091809</ArticleId><ArticleId IdType="pmc">4473839</ArticleId><ArticleId IdType="doi">10.1186/s40478-015-0215-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. LATE-NC staging in routine neuropathologic diagnosis: an update. Acta Neuropathol. 145, 159&#x2013;173 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36512061</ArticleId><ArticleId IdType="doi">10.1007/s00401-022-02524-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. et al. Staging TDP-43 pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 127, 441&#x2013;450 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24240737</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1211-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. et al. Updated TDP-43 in Alzheimer&#x2019;s disease staging scheme. Acta Neuropathol. 131, 571&#x2013;585 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26810071</ArticleId><ArticleId IdType="pmc">5946692</ArticleId><ArticleId IdType="doi">10.1007/s00401-016-1537-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. &amp; Dickson, D. W. TDP-43 in the olfactory bulb in Alzheimer&#x2019;s disease. Neuropathol. Appl. Neurobiol. 42, 390&#x2013;393 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26810591</ArticleId><ArticleId IdType="pmc">5154242</ArticleId><ArticleId IdType="doi">10.1111/nan.12309</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio, A. et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41, 118&#x2013;130 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23860588</ArticleId><ArticleId IdType="doi">10.1159/000351153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet 377, 942&#x2013;955 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Bersano, E. et al. Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 373&#x2013;379 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32484726</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1771732</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford, C. et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology 91, e1370&#x2013;e1380 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30209236</ArticleId><ArticleId IdType="pmc">6177274</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan, J., Pender, N. P. &amp; Hardiman, O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 6, 994&#x2013;1003 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17945153</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli, P. &amp; Brown, R. H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 7, 710&#x2013;723 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16924260</ArticleId><ArticleId IdType="doi">10.1038/nrn1971</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman, E. L. et al. Amyotrophic lateral sclerosis. Lancet 400, 1363&#x2013;1380 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36116464</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)01272-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, R. H. &amp; Al-Chalabi, A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 377, 162&#x2013;172 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia, R., Chio, A. &amp; Traynor, B. J. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 17, 94&#x2013;102 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29154141</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante, S., Rouleau, G. A. &amp; Kabashi, E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum. Mutat. 34, 812&#x2013;826 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23559573</ArticleId><ArticleId IdType="doi">10.1002/humu.22319</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes, C. H., Shephard, B. C., Geddes, J. F., Body, G. D. &amp; Martin, J. E. Olfactory disorder in motor neuron disease. Exp. Neurol. 150, 248&#x2013;253 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9527894</ArticleId><ArticleId IdType="doi">10.1006/exnr.1997.6773</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda, T. et al. TDP-43 pathology progression along the olfactory pathway as a possible substrate for olfactory impairment in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 74, 547&#x2013;556 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25933387</ArticleId><ArticleId IdType="doi">10.1097/NEN.0000000000000198</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski, M. D. et al. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 6, 28 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29653597</ArticleId><ArticleId IdType="pmc">5899326</ArticleId><ArticleId IdType="doi">10.1186/s40478-018-0528-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori, F. et al. Phosphorylated TDP-43 aggregates in skeletal and cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis and various conditions. Acta Neuropathol. Commun. 7, 165 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31661037</ArticleId><ArticleId IdType="pmc">6816170</ArticleId><ArticleId IdType="doi">10.1186/s40478-019-0824-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa, F. et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron 102, 339&#x2013;357.e7 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30853299</ArticleId><ArticleId IdType="pmc">6548321</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, E. B., Lee, V. M. &amp; Trojanowski, J. Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13, 38&#x2013;50 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22127299</ArticleId><ArticleId IdType="pmc">3285250</ArticleId><ArticleId IdType="doi">10.1038/nrn3121</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Z. S. Does a loss of TDP-43 function cause neurodegeneration? Mol. Neurodegener. 7, 27 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22697423</ArticleId><ArticleId IdType="pmc">3419078</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-7-27</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, E. S. et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl Acad. Sci. USA 110, E736&#x2013;E745 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23382207</ArticleId><ArticleId IdType="pmc">3581922</ArticleId><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin, J. A. et al. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. Proc. Natl Acad. Sci. USA 111, 4309&#x2013;4314 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24591609</ArticleId><ArticleId IdType="pmc">3964094</ArticleId><ArticleId IdType="doi">10.1073/pnas.1317317111</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada, S. J. et al. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 30, 639&#x2013;649 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20071528</ArticleId><ArticleId IdType="pmc">2821110</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanden Broeck, L., Callaerts, P. &amp; Dermaut, B. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis? Trends Mol. Med. 20, 66&#x2013;71 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24355761</ArticleId><ArticleId IdType="doi">10.1016/j.molmed.2013.11.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann, E. et al. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). J. Biol. Chem. 287, 23079&#x2013;23094 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22563080</ArticleId><ArticleId IdType="pmc">3391091</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111.328757</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk, L. et al. Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72. J. Neuropathol. Exp. Neurol. 73, 837&#x2013;845 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25111021</ArticleId><ArticleId IdType="doi">10.1097/NEN.0000000000000102</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz, L. et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One 5, e13250 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20948999</ArticleId><ArticleId IdType="pmc">2952586</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0013250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann, J. R. et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron 102, 321&#x2013;338.e8 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30826182</ArticleId><ArticleId IdType="pmc">6472983</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.01.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W. et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat. Med. 22, 869&#x2013;878 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27348499</ArticleId><ArticleId IdType="pmc">4974139</ArticleId><ArticleId IdType="doi">10.1038/nm.4130</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W. et al. Motor-coordinative and cognitive dysfunction caused by mutant TDP-43 could be reversed by inhibiting its mitochondrial localization. Mol. Ther. 25, 127&#x2013;139 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28129109</ArticleId><ArticleId IdType="pmc">5363201</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2016.10.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio, A., Mazzini, L. &amp; Mora, G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 167, 107986 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32062193</ArticleId><ArticleId IdType="doi">10.1016/j.neuropharm.2020.107986</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall, L. et al. Molecular and cellular mechanisms affected in ALS. J. Pers. Med. 10, 101 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32854276</ArticleId><ArticleId IdType="pmc">7564998</ArticleId><ArticleId IdType="doi">10.3390/jpm10030101</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini, R. et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front. Neurosci. 13, 1310 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31866818</ArticleId><ArticleId IdType="pmc">6909825</ArticleId><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, J., Wang, L., Yan, T., Perry, G. &amp; Wang, X. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration. Mol. Cell Neurosci. 100, 103396 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31445085</ArticleId><ArticleId IdType="pmc">6874890</ArticleId><ArticleId IdType="doi">10.1016/j.mcn.2019.103396</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron, T. F., Josephs, K. A. &amp; Petrucelli, L. Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Neuropathol. Appl. Neurobiol. 36, 97&#x2013;112 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20202122</ArticleId><ArticleId IdType="pmc">3052765</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2990.2010.01060.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Loganathan, S., Lehmkuhl, E. M., Eck, R. J. &amp; Zarnescu, D. C. To be or not to be &#x2026; toxic &#x2014; is RNA association with TDP-43 complexes deleterious or protective in neurodegeneration? Front. Mol. Biosci. 6, 154 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31998750</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2019.00154</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es, M. A. et al. Amyotrophic lateral sclerosis. Lancet 390, 2084&#x2013;2098 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary, D. et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51, 1546&#x2013;1554 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId><ArticleId IdType="doi">10.1212/WNL.51.6.1546</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieben, A. et al. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol. 124, 353&#x2013;372 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22890575</ArticleId><ArticleId IdType="pmc">3422616</ArticleId><ArticleId IdType="doi">10.1007/s00401-012-1029-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns, N. J. et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol. 114, 5&#x2013;22 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17579875</ArticleId><ArticleId IdType="pmc">2827877</ArticleId><ArticleId IdType="doi">10.1007/s00401-007-0237-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 119, 1&#x2013;4 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19924424</ArticleId><ArticleId IdType="doi">10.1007/s00401-009-0612-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashley, T., Rohrer, J. D., Mead, S. &amp; Revesz, T. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol. Appl. Neurobiol. 41, 858&#x2013;881 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26041104</ArticleId><ArticleId IdType="doi">10.1111/nan.12250</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso, S. M. et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 126, 2016&#x2013;2022 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12876142</ArticleId><ArticleId IdType="doi">10.1093/brain/awg204</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyike, C. U. &amp; Huey, E. D. Frontotemporal dementia and psychiatry. Int. Rev. Psychiatry 25, 127&#x2013;129 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23611342</ArticleId><ArticleId IdType="pmc">3947598</ArticleId><ArticleId IdType="doi">10.3109/09540261.2013.785169</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann, G. et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology 34, 939&#x2013;944 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456&#x2013;2477 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21810890</ArticleId><ArticleId IdType="pmc">3170532</ArticleId><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006&#x2013;1014 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21325651</ArticleId><ArticleId IdType="pmc">3059138</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden, J. S., Neary, D. &amp; Mann, D. M. Frontotemporal dementia. Br. J. Psychiatry 180, 140&#x2013;143 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11823324</ArticleId><ArticleId IdType="doi">10.1192/bjp.180.2.140</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider, J. et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 127, 423&#x2013;439 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24407427</ArticleId><ArticleId IdType="pmc">3971993</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1238-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell, J. R. et al. The frontotemporal dementia-motor neuron disease continuum. Lancet 388, 919&#x2013;931 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26987909</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(16)00737-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer, J. D. et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 75, 2204&#x2013;2211 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21172843</ArticleId><ArticleId IdType="pmc">3013589</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318202038c</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell, J. L. et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology 75, 2212&#x2013;2220 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21172844</ArticleId><ArticleId IdType="pmc">3013590</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31820203c2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111&#x2013;113 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21644037</ArticleId><ArticleId IdType="pmc">3285143</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, E. B. et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 134, 65&#x2013;78 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28130640</ArticleId><ArticleId IdType="pmc">5521959</ArticleId><ArticleId IdType="doi">10.1007/s00401-017-1679-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M., Lee, E. B. &amp; Mackenzie, I. R. Frontotemporal lobar degeneration TDP-43-immunoreactive pathological subtypes: clinical and mechanistic significance. Adv. Exp. Med. Biol. 1281, 201&#x2013;217 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33433877</ArticleId><ArticleId IdType="pmc">8183578</ArticleId><ArticleId IdType="doi">10.1007/978-3-030-51140-1_13</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916&#x2013;919 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId><ArticleId IdType="doi">10.1038/nature05016</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin, V. M. et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet. 42, 234&#x2013;239 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20154673</ArticleId><ArticleId IdType="pmc">2828525</ArticleId><ArticleId IdType="doi">10.1038/ng.536</ArticleId></ArticleIdList></Reference><Reference><Citation>Finger, E. C. Frontotemporal dementias. Continuum 22, 464&#x2013;489 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27042904</ArticleId><ArticleId IdType="pmc">5390934</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, J. L. et al. Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain 143, 2844&#x2013;2857 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32830216</ArticleId><ArticleId IdType="pmc">7526723</ArticleId><ArticleId IdType="doi">10.1093/brain/awaa219</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser, F. et al. Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch. Neurol. 67, 1238&#x2013;1250 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20937952</ArticleId><ArticleId IdType="pmc">3050578</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2010.254</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese, K. E. et al. TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with Lewy bodies and ageing. Brain Pathol. 27, 472&#x2013;479 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27495267</ArticleId><ArticleId IdType="doi">10.1111/bpa.12424</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan, S. et al. Sex differences in Alzheimer&#x2019;s disease and common neuropathologies of aging. Acta Neuropathol. 136, 887&#x2013;900 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30334074</ArticleId><ArticleId IdType="pmc">6279593</ArticleId><ArticleId IdType="doi">10.1007/s00401-018-1920-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser, L. M. et al. The revised national Alzheimer&#x2019;s coordinating center&#x2019;s neuropathology form &#x2014; available data and new analyses. J. Neuropathol. Exp. Neurol. 77, 717&#x2013;726 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29945202</ArticleId><ArticleId IdType="pmc">6044344</ArticleId><ArticleId IdType="doi">10.1093/jnen/nly049</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata, Y., Fardo, D. W., Kukull, W. A. &amp; Nelson, P. T. Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer&#x2019;s disease and cerebrovascular disease pathologies. Acta Neuropathol. Commun. 6, 142 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30567576</ArticleId><ArticleId IdType="pmc">6299605</ArticleId><ArticleId IdType="doi">10.1186/s40478-018-0641-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, L. et al. The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology 84, 927&#x2013;934 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25653292</ArticleId><ArticleId IdType="pmc">4351662</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001313</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugan, A. J. et al. Analysis of genes (TMEM106B, GRN, ABCC9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study. Acta Neuropathol. Commun. 9, 152 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34526147</ArticleId><ArticleId IdType="pmc">8442328</ArticleId><ArticleId IdType="doi">10.1186/s40478-021-01250-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, H. S. et al. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE &#x3b5;4 haplotype status: a community-based cohort study. Lancet Neurol. 17, 773&#x2013;781 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30093249</ArticleId><ArticleId IdType="pmc">6154505</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(18)30251-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg, A. M. et al. Association of apolipoprotein E &#x3b5;4 with transactive response DNA-binding protein 43. JAMA Neurol. 75, 1347&#x2013;1354 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30422173</ArticleId><ArticleId IdType="pmc">6248121</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.3139</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham, G. W. et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet. 10, e1004606 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25188341</ArticleId><ArticleId IdType="pmc">4154667</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1004606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino, E. C. et al. Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82, 1760&#x2013;1767 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24748674</ArticleId><ArticleId IdType="pmc">4035706</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000431</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, L., Boyle, P. A., Leurgans, S., Schneider, J. A. &amp; Bennett, D. A. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol. Aging 35, 819&#x2013;826 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24199961</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.10.074</ArticleId></ArticleIdList></Reference><Reference><Citation>Power, M. C. et al. Combined neuropathological pathways account for age-related risk of dementia. Ann. Neurol. 84, 10&#x2013;22 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29944741</ArticleId><ArticleId IdType="pmc">6119518</ArticleId><ArticleId IdType="doi">10.1002/ana.25246</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol. 20, 66&#x2013;79 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19021630</ArticleId><ArticleId IdType="doi">10.1111/j.1750-3639.2008.00244.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi, A. et al. Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging. Neurology 95, e1951&#x2013;e1962 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32753441</ArticleId><ArticleId IdType="pmc">7682843</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000010454</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison, W. T. et al. Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is independently associated with dementia and strongly associated with arteriolosclerosis in the oldest-old. Acta Neuropathol. 142, 917&#x2013;919 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34415381</ArticleId><ArticleId IdType="pmc">8816525</ArticleId><ArticleId IdType="doi">10.1007/s00401-021-02360-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, J. L. et al. Non-Alzheimer&#x2019;s contributions to dementia and cognitive resilience in the 90+ Study. Acta Neuropathol. 136, 377&#x2013;388 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29916037</ArticleId><ArticleId IdType="pmc">6534149</ArticleId><ArticleId IdType="doi">10.1007/s00401-018-1872-5</ArticleId></ArticleIdList></Reference><Reference><Citation>James, B. D., Bennett, D. A., Boyle, P. A., Leurgans, S. &amp; Schneider, J. A. Dementia from Alzheimer disease and mixed pathologies in the oldest old. J. Am. Med. Assoc. 307, 1798&#x2013;1800 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.3556</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag, S. et al. Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents. Neurology 95, e2056&#x2013;e2064 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32759188</ArticleId><ArticleId IdType="pmc">7713750</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000010602</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker, D. W., Gazmararian, J. A., Sudano, J. &amp; Patterson, M. The association between age and health literacy among elderly persons. J. Gerontol. B Psychol. Sci. Soc. Sci. 55, S368&#x2013;S374 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11078114</ArticleId><ArticleId IdType="doi">10.1093/geronb/55.6.S368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudore, R. L. et al. Limited literacy and mortality in the elderly: the health, aging, and body composition study. J. Gen. Intern. Med. 21, 806&#x2013;812 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16881938</ArticleId><ArticleId IdType="pmc">1831586</ArticleId><ArticleId IdType="doi">10.1111/j.1525-1497.2006.00539.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle, P. A. et al. Cognitive decline impairs financial and health literacy among community-based older persons without dementia. Psychol. Aging 28, 614&#x2013;624 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23957225</ArticleId><ArticleId IdType="pmc">3778113</ArticleId><ArticleId IdType="doi">10.1037/a0033103</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, S. D., Boyle, P. A., James, B. D., Yu, L. &amp; Bennett, D. A. Poorer financial and health literacy among community-dwelling older adults with mild cognitive impairment. J. Aging Health 27, 1105&#x2013;1117 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25903976</ArticleId><ArticleId IdType="pmc">4520748</ArticleId><ArticleId IdType="doi">10.1177/0898264315577780</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, R. S., Yu, L., James, B. D., Bennett, D. A. &amp; Boyle, P. A. Association of financial and health literacy with cognitive health in old age. Neuropsychol. Dev. Cogn. B Aging Neuropsychol. Cogn. 24, 186&#x2013;197 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27263546</ArticleId><ArticleId IdType="doi">10.1080/13825585.2016.1178210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, L., Wilson, R. S., Schneider, J. A., Bennett, D. A. &amp; Boyle, P. A. Financial and health literacy predict incident Alzheimer&#x2019;s disease dementia and pathology. J. Alzheimers Dis. 56, 1485&#x2013;1493 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28157101</ArticleId><ArticleId IdType="pmc">5444544</ArticleId><ArticleId IdType="doi">10.3233/JAD-161132</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi, A. et al. Association of TDP-43 pathology with domain-specific literacy in older persons. Alzheimer Dis. Assoc. Disord. 33, 315&#x2013;320 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31305319</ArticleId><ArticleId IdType="pmc">6878155</ArticleId><ArticleId IdType="doi">10.1097/WAD.0000000000000334</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser, L. M., Teylan, M. A. &amp; Nelson, P. T. Limbic predominant age-related TDP-43 encephalopathy (LATE): clinical and neuropathological associations. J. Neuropathol. Exp. Neurol. 79, 305&#x2013;313 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31845964</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlz126</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis, Z., Wilson, R. S., Li, Y., Aggarwal, N. T. &amp; Bennett, D. A. Diabetes and function in different cognitive systems in older individuals without dementia. Diabetes Care 29, 560&#x2013;565 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16505506</ArticleId><ArticleId IdType="doi">10.2337/diacare.29.03.06.dc05-1901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou, M. A. et al. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 72, 905&#x2013;911 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26030836</ArticleId><ArticleId IdType="pmc">4975611</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.0910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa, D., Kamel, F., Bellocco, R., Ye, W. &amp; Fang, F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur. J. Neurol. 22, 1436&#x2013;1442 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25600257</ArticleId><ArticleId IdType="pmc">4506907</ArticleId><ArticleId IdType="doi">10.1111/ene.12632</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan, S. et al. Association of hemoglobin A1C with TDP-43 pathology in community-based elders. Neurology 96, e2694&#x2013;e2703 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33853892</ArticleId><ArticleId IdType="pmc">8205465</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000012025</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai, T. et al. Phosphorylated TDP-43 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol. 117, 125&#x2013;136 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19139911</ArticleId><ArticleId IdType="doi">10.1007/s00401-008-0480-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 70, 1850&#x2013;1857 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18401022</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000304041.09418.b1</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer&#x2019;s disease impact clinical features. Ann. Neurol. 78, 697&#x2013;709 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26224156</ArticleId><ArticleId IdType="pmc">4623932</ArticleId><ArticleId IdType="doi">10.1002/ana.24493</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. et al. TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol. 127, 811&#x2013;824 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24659241</ArticleId><ArticleId IdType="pmc">4172544</ArticleId><ArticleId IdType="doi">10.1007/s00401-014-1269-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. et al. Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol. 137, 227&#x2013;238 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30604226</ArticleId><ArticleId IdType="pmc">6358471</ArticleId><ArticleId IdType="doi">10.1007/s00401-018-1951-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 134, 1506&#x2013;1518 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21596774</ArticleId><ArticleId IdType="pmc">3097889</ArticleId><ArticleId IdType="doi">10.1093/brain/awr053</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawe, R. J., Bennett, D. A., Schneider, J. A. &amp; Arfanakis, K. Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study. PLoS One 6, e26286 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22043314</ArticleId><ArticleId IdType="pmc">3197137</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0026286</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, L. et al. Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons. Neurology 94, e142&#x2013;e152 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31757868</ArticleId><ArticleId IdType="pmc">6988988</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000008679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow, C., Weiner, M. W., Ellis, W. G. &amp; Chui, H. C. Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample. Brain Behav. 2, 435&#x2013;442 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22950047</ArticleId><ArticleId IdType="pmc">3432966</ArticleId><ArticleId IdType="doi">10.1002/brb3.66</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. &amp; Dickson, D. W. Hippocampal sclerosis in tau-negative frontotemporal lobar degeneration. Neurobiol. Aging 28, 1718&#x2013;1722 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16930776</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.07.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray, M. E. et al. Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72. Acta Neuropathol. 126, 545&#x2013;554 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23922030</ArticleId><ArticleId IdType="pmc">3926101</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1161-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Popkirov, S. et al. Progressive hippocampal sclerosis after viral encephalitis: potential role of NMDA receptor antibodies. Seizure 51, 6&#x2013;8 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28750305</ArticleId><ArticleId IdType="doi">10.1016/j.seizure.2017.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Thom, M. et al. Temporal lobe sclerosis associated with hippocampal sclerosis in temporal lobe epilepsy: neuropathological features. J. Neuropathol. Exp. Neurol. 68, 928&#x2013;938 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19606061</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e3181b05d67</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson, D. W. et al. Hippocampal sclerosis: a common pathological feature of dementia in very old (&gt; or = 80 years of age) humans. Acta Neuropathol. 88, 212&#x2013;221 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7810292</ArticleId><ArticleId IdType="doi">10.1007/BF00293396</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol. 126, 161&#x2013;177 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23864344</ArticleId><ArticleId IdType="pmc">3889169</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1154-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Neltner, J. H. et al. Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain 137, 255&#x2013;267 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24271328</ArticleId><ArticleId IdType="doi">10.1093/brain/awt318</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthreaux, K. M. et al. Limbic-predominant age-related TDP-43 encephalopathy: medical and pathologic factors associated with comorbid hippocampal sclerosis. Neurology 98, e1422&#x2013;e1433 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35121671</ArticleId><ArticleId IdType="pmc">8992604</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000200001</ArticleId></ArticleIdList></Reference><Reference><Citation>Pao, W. C. et al. Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer Dis. Assoc. Disord. 25, 364&#x2013;368 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21346515</ArticleId><ArticleId IdType="pmc">3107353</ArticleId><ArticleId IdType="doi">10.1097/WAD.0b013e31820f8f50</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokkanen, S. R. K. et al. Putative risk alleles for LATE-NC with hippocampal sclerosis in population-representative autopsy cohorts. Brain Pathol. 30, 364&#x2013;372 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31376286</ArticleId><ArticleId IdType="doi">10.1111/bpa.12773</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol. 127, 825&#x2013;843 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24770881</ArticleId><ArticleId IdType="pmc">4113197</ArticleId><ArticleId IdType="doi">10.1007/s00401-014-1282-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. ABCC9/SUR2 in the brain: implications for hippocampal sclerosis of aging and a potential therapeutic target. Ageing Res. Rev. 24, 111&#x2013;125 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26226329</ArticleId><ArticleId IdType="pmc">4661124</ArticleId><ArticleId IdType="doi">10.1016/j.arr.2015.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. TDP-43 proteinopathy in aging: associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels. Neurobiol. Dis. 125, 67&#x2013;76 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30682540</ArticleId><ArticleId IdType="pmc">6696921</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2019.01.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Morte, B. &amp; Bernal, J. Thyroid hormone action: astrocyte-neuron communication. Front. Endocrinol. 5, 82 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2014.00082</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda, H. et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 114, 221&#x2013;229 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17653732</ArticleId><ArticleId IdType="doi">10.1007/s00401-007-0261-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi, S. et al. Concurrence of TDP-43, tau and &#x3b1;-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res. 1184, 284&#x2013;294 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17963732</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2007.09.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura, M. T. et al. Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathol. 143, 15&#x2013;31 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34854996</ArticleId><ArticleId IdType="doi">10.1007/s00401-021-02383-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal, S. et al. The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer&#x2019;s dementia in older persons. Acta Neuropathol. Commun. 9, 156 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34563269</ArticleId><ArticleId IdType="pmc">8466680</ArticleId><ArticleId IdType="doi">10.1186/s40478-021-01260-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins, B. L. et al. Brain arteriolosclerosis. Acta Neuropathol. 141, 1&#x2013;24 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33098484</ArticleId><ArticleId IdType="doi">10.1007/s00401-020-02235-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Ighodaro, E. T. et al. Risk factors and global cognitive status related to brain arteriolosclerosis in elderly individuals. J. Cereb. Blood Flow. Metab. 37, 201&#x2013;216 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">26738751</ArticleId><ArticleId IdType="doi">10.1177/0271678X15621574</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourassa, P., Tremblay, C., Schneider, J. A., Bennett, D. A. &amp; Calon, F. Brain mural cell loss in the parietal cortex in Alzheimer&#x2019;s disease correlates with cognitive decline and TDP-43 pathology. Neuropathol. Appl. Neurobiol. 46, 458&#x2013;477 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31970820</ArticleId><ArticleId IdType="pmc">7739958</ArticleId><ArticleId IdType="doi">10.1111/nan.12599</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal, S. et al. Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change and microvascular pathologies in community-dwelling older persons. Brain Pathol. 31, e12939 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33624322</ArticleId><ArticleId IdType="pmc">8363209</ArticleId><ArticleId IdType="doi">10.1111/bpa.12939</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755&#x2013;766 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25348064</ArticleId><ArticleId IdType="pmc">4257842</ArticleId><ArticleId IdType="doi">10.1007/s00401-014-1349-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs, K. A. et al. Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol. 133, 705&#x2013;715 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28160067</ArticleId><ArticleId IdType="pmc">6091858</ArticleId><ArticleId IdType="doi">10.1007/s00401-017-1681-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, X. et al. Phosphorylated TDP-43 staging of primary age-related tauopathy. Neurosci. Bull. 35, 183&#x2013;192 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30382507</ArticleId><ArticleId IdType="doi">10.1007/s12264-018-0300-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe, M. J. et al. Differential diagnosis of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC. Alzheimers Dement. 19, 1234&#x2013;1244 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35971593</ArticleId><ArticleId IdType="doi">10.1002/alz.12763</ArticleId></ArticleIdList></Reference><Reference><Citation>Makkinejad, N. et al. Associations of amygdala volume and shape with transactive response DNA-binding protein 43 (TDP-43) pathology in a community cohort of older adults. Neurobiol. Aging 77, 104&#x2013;111 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30784812</ArticleId><ArticleId IdType="pmc">6486844</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.01.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, H. X., Tanji, K., Mori, F. &amp; Wakabayashi, K. Epitope mapping of 2E2-D3, a monoclonal antibody directed against human TDP-43. Neurosci. Lett. 434, 170&#x2013;174 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18304732</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2008.01.060</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg, E., Gray, E., Ansorge, O., Talbot, K. &amp; Turner, M. R. Towards a TDP-43-based biomarker for ALS and FTLD. Mol. Neurobiol. 55, 7789&#x2013;7801 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29460270</ArticleId><ArticleId IdType="pmc">6132775</ArticleId><ArticleId IdType="doi">10.1007/s12035-018-0947-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder, V., Gregory, J. M., Barria, M. A., Green, A. &amp; Pal, S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 18, 90 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29954341</ArticleId><ArticleId IdType="pmc">6027783</ArticleId><ArticleId IdType="doi">10.1186/s12883-018-1091-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulds, P. et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Acta Neuropathol. 116, 141&#x2013;146 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18506455</ArticleId><ArticleId IdType="pmc">2464623</ArticleId><ArticleId IdType="doi">10.1007/s00401-008-0389-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulds, P. G. et al. Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol. 118, 647&#x2013;658 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19823856</ArticleId><ArticleId IdType="pmc">2809136</ArticleId><ArticleId IdType="doi">10.1007/s00401-009-0594-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami, M., Taylor, J. P. &amp; Parker, R. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell 154, 727&#x2013;736 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23953108</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.07.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad, A. et al. An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models. Sci. Rep. 6, 39490 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">28000730</ArticleId><ArticleId IdType="pmc">5175139</ArticleId><ArticleId IdType="doi">10.1038/srep39490</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker, S. J. et al. Inhibition of TDP-43 accumulation by bis(thiosemicarbazonato)-copper complexes. PLoS One 7, e42277 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22879928</ArticleId><ArticleId IdType="pmc">3411774</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0042277</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, I. F. et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc. Natl Acad. Sci. USA 109, 15024&#x2013;15029 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22932872</ArticleId><ArticleId IdType="pmc">3443184</ArticleId><ArticleId IdType="doi">10.1073/pnas.1206362109</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems, S., Bogaert, E., Van Damme, P. &amp; Van Den Bosch, L. Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol. 132, 159&#x2013;173 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27271576</ArticleId><ArticleId IdType="pmc">4947127</ArticleId><ArticleId IdType="doi">10.1007/s00401-016-1586-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann, D. &amp; Haass, C. TDP-43 and FUS: a nuclear affair. Trends Neurosci. 34, 339&#x2013;348 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21700347</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2011.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. J. &amp; Taylor, J. P. Lost in transportation: nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron 96, 285&#x2013;297 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29024655</ArticleId><ArticleId IdType="pmc">5678982</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.07.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, K. et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26308891</ArticleId><ArticleId IdType="pmc">4800742</ArticleId><ArticleId IdType="doi">10.1038/nature14973</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou, C. C. et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci. 21, 228&#x2013;239 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29311743</ArticleId><ArticleId IdType="pmc">5800968</ArticleId><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle, H. et al. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci. Rep. 8, 7084 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29728564</ArticleId><ArticleId IdType="pmc">5935713</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-25007-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Portz, B., Lee, B. L. &amp; Shorter, J. FUS and TDP-43 phases in health and disease. Trends Biochem. Sci. 46, 550&#x2013;563 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33446423</ArticleId><ArticleId IdType="pmc">8195841</ArticleId><ArticleId IdType="doi">10.1016/j.tibs.2020.12.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado, D. A. &amp; Davidson, B. L. Gene therapy for ALS: a review. Mol. Ther. 29, 3345&#x2013;3358 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33839324</ArticleId><ArticleId IdType="pmc">8636154</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard, A. ALS antisense drug falters in phase III. Nat. Rev. Drug Discov. 20, 883&#x2013;885 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34716445</ArticleId><ArticleId IdType="doi">10.1038/d41573-021-00181-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, H. et al. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2, 209&#x2013;217 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12934714</ArticleId><ArticleId IdType="doi">10.1046/j.1474-9728.2003.00054.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura, A. L. et al. Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells. PLoS One 9, e91269 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24651281</ArticleId><ArticleId IdType="pmc">3961241</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0091269</ArticleId></ArticleIdList></Reference><Reference><Citation>Morata-Tarifa, C., Azkona, G., Glass, J., Mazzini, L. &amp; Sanchez-Pernaute, R. Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis. NPJ Regen. Med. 6, 20 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33795700</ArticleId><ArticleId IdType="pmc">8016966</ArticleId><ArticleId IdType="doi">10.1038/s41536-021-00131-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter, J. Engineering therapeutic protein disaggregases. Mol. Biol. Cell 27, 1556&#x2013;1560 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27255695</ArticleId><ArticleId IdType="pmc">4865313</ArticleId><ArticleId IdType="doi">10.1091/mbc.E15-10-0693</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack, K. L. &amp; Shorter, J. Engineering and evolution of molecular chaperones and protein disaggregases with enhanced activity. Front. Mol. Biosci. 3, 8 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27014702</ArticleId><ArticleId IdType="pmc">4791398</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2016.00008</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq, A. et al. Mining disaggregase sequence space to safely counter TDP-43, FUS, and &#x3b1;-synuclein proteotoxicity. Cell Rep. 28, 2080&#x2013;2095.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31433984</ArticleId><ArticleId IdType="pmc">6750954</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2019.07.069</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris, E. Large autopsy study estimates prevalence of &#x201c;LATE&#x201d; neuropathologic change. J. Am. Med. Assoc. 328, 815&#x2013;816 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11513</ArticleId></ArticleIdList></Reference><Reference><Citation>He, W., Goodkind, D. &amp; Kowal, P. in Population Reports, P95/16-1 (eds. International US Census Bureau) (US Government Publication Office, 2016).</Citation></Reference><Reference><Citation>Bigio, E. H. TDP-43 variants of frontotemporal lobar degeneration. J. Mol. Neurosci. 45, 390&#x2013;401 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21607722</ArticleId><ArticleId IdType="pmc">3202017</ArticleId><ArticleId IdType="doi">10.1007/s12031-011-9545-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie, I. R. &amp; Neumann, M. Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathol. 134, 79&#x2013;96 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28466142</ArticleId><ArticleId IdType="doi">10.1007/s00401-017-1716-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky, P. J. et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat. Struct. Mol. Biol. 20, 1443&#x2013;1449 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24240615</ArticleId><ArticleId IdType="doi">10.1038/nsmb.2698</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser, F. et al. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol. 115, 133&#x2013;145 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17713769</ArticleId><ArticleId IdType="doi">10.1007/s00401-007-0257-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima, T. et al. Perry syndrome: a distinctive type of TDP-43 proteinopathy. J. Neuropathol. Exp. Neurol. 76, 676&#x2013;682 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28789478</ArticleId><ArticleId IdType="pmc">5901076</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlx049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider, C. et al. Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat. Disord. 15, 281&#x2013;286 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18723384</ArticleId><ArticleId IdType="doi">10.1016/j.parkreldis.2008.07.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson, Y. S. et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer&#x2019;s disease, late onset Alzheimer&#x2019;s disease and Down&#x2019;s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol. 122, 703&#x2013;713 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21968532</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0879-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa, C. F. et al. Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and down syndrome. Arch. Neurol. 66, 1483&#x2013;1488 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20008652</ArticleId><ArticleId IdType="pmc">2864642</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2009.277</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman, S. H., Spires-Jones, T., Hyman, B. T., Growdon, J. H. &amp; Frosch, M. P. TAR-DNA binding protein 43 in Pick disease. J. Neuropathol. Exp. Neurol. 67, 62&#x2013;67 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18091558</ArticleId><ArticleId IdType="doi">10.1097/nen.0b013e3181609361</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujishiro, H. et al. Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol. 117, 151&#x2013;158 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19039597</ArticleId><ArticleId IdType="doi">10.1007/s00401-008-0463-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa, M. et al. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130, 1386&#x2013;1394 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17439983</ArticleId><ArticleId IdType="doi">10.1093/brain/awm065</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, C. F. et al. Selective occurrence of TDP-43-immunoreactive inclusions in the lower motor neurons in Machado-Joseph disease. Acta Neuropathol. 118, 553&#x2013;560 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19526244</ArticleId><ArticleId IdType="doi">10.1007/s00401-009-0552-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoshima, Y. et al. Spinocerebellar ataxia type 2 (SCA2) is associated with TDP-43 pathology. Acta Neuropathol. 122, 375&#x2013;378 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21830155</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0862-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai, A., Makioka, K., Fukuda, T., Takatama, M. &amp; Okamoto, K. Accumulation of phosphorylated TDP-43 in the CNS of a patient with Cockayne syndrome. Neuropathology 33, 673&#x2013;677 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23581709</ArticleId><ArticleId IdType="doi">10.1111/neup.12038</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker, A. K. et al. Astrocytic TDP-43 pathology in Alexander disease. J. Neurosci. 34, 6448&#x2013;6458 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24806671</ArticleId><ArticleId IdType="pmc">4012304</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0248-14.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, D. A. et al. Religious orders study and rush memory and aging project. J. Alzheimers Dis. 64, S161&#x2013;S189 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29865057</ArticleId><ArticleId IdType="pmc">6380522</ArticleId><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischman, D. A. et al. Regional brain cortical thinning and systemic inflammation in older persons without dementia. J. Am. Geriatr. Soc. 58, 1823&#x2013;1825 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20863359</ArticleId><ArticleId IdType="pmc">2945260</ArticleId><ArticleId IdType="doi">10.1111/j.1532-5415.2010.03049.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag, S. et al. Ex vivo MRI facilitates localization of cerebral microbleeds of different ages during neuropathology assessment. Free Neuropathol. 2, 2&#x2013;35 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">37284642</ArticleId><ArticleId IdType="pmc">10209859</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>